PARIS, Sept 25 (Reuters) - Ipsen has submitted a six-month sustained version of its prostate cancer treatment Decapeptyl for marketing approval with European health authorities, the French drugmaker ...
PARIS, Feb 7 (Reuters) - Ipsen said a late-stage study of its Decapeptyl drug when injected into patients with locally advanced or metastatic prostate cancer was positive. The results matched the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback